Imagine a surgeon wearing high-tech glasses that project a 3D map of a patient's organs directly onto their body during surgery. Instead of guessing where a tumor ends based on flat 2D scans, they can see exactly where the cancer is and where healthy tissue begins in real-time. It is like having a high-definition GPS and a microscopic lab combined right inside the operating room.
Surgeons rely on subjective interpretations of 2D images, leading to high complication rates in liver and pancreatic surgeries. There is a critical lack of real-time, cell-level data to ensure complete tumor removal during operations.
An AI-based medical system that fuses imaging modalities into 3D holograms, provides real-time surgical navigation, and enables point-of-care cell-level diagnostics.
If you are a device manufacturer dealing with the high rate of surgical complications in liver and pancreatic cancer—this project developed an AI-based 3D holographic tool that fuses imaging modalities to reduce subjective interpretation. This allows for more objective decision-making during the procedure.
If you are a software company dealing with the limitation of 2D scans that miss lesions in 50% of pancreatic tail cases—this project developed automatic fusion and segmentation of imaging modalities. This provides a 3D visualization of key structures like vessels to prevent accidental damage.
If you are a hospital dealing with postoperative morbidity rates up to 15%—this project developed a real-time cell-level cancer diagnostic tool. This ensures that no diseased cells remain inside the patient during the resection process.
Based on available project data, specific pricing and cost structures are not provided.
The project aims for a market-ready solution and is led by HoloCare AS, which has already developed a CE-approved product, suggesting a path to industrial scale.
Based on available project data, the specific IP and licensing agreements between the 15 partners are not disclosed.
The system integrates with state-of-the-art imaging modalities such as CT, MRI, and ultrasound to create fused 3D holographic models.
The project period runs from 2024-01-01 to 2027-12-31, indicating the development and validation phase concludes at the end of 2027.
The consortium is well-balanced for commercialization, consisting of 15 partners across 10 countries. With a 20% industry ratio (3 industrial partners, including 2 SMEs), the project blends academic research (5 universities, 4 research centers) with commercial drive. The leadership by HoloCare AS, an SME with a track record of CE-approved products, significantly lowers the risk of the technology remaining purely theoretical.
Contact HOLOCARE AS in Norway
Contact us to explore licensing opportunities for 3D holographic surgical guidance.
